

Supplementary table 1. Clinical and laboratory characteristics of the 31 AML cases and 30 controls.

Characteristics	AML Patient	Healthy control
Male/female	15/16	15/15
Age at study entry, year, median (range)	46 (15-69)	49 (20-73)
Bone marrow blasts at diagnosis, %, median (interquartile range)	73 (26-96)	/
WBC at diagnosis, $\times 10^9/L$, median (interquartile range)	31.7 (0.82-467)	/
Cytogenetic risk group, no./total no. (%)		
Favorable	10/31	/
Unfavorable	19/31	/
Missing data	2/31	/
Status after the first course of chemotherapy, no./total no. (%)		
CR	18/31	/
Not CR	11/31	/
Unavailable data	2/31	/
AML FAB subtype, no./total no. (%)		
AML with minimal differentiation: M0	0/31	/
AML without maturation: M1	1/31	/
AML with maturation: M2	2/31	/
Acute Promyelocytic leukemia: M3	7/31	/
Acute Myelomonocytic leukemia: M4	3/31	/
Acute monoblastic or monocytic leukemia: M5	14/31	/
Acute erythroid leukemia: M6	0/31	/
Acute megakaryoblastic leukemia: M7	0/31	/
Other subtype	4/31	/

WBC: white blood cell; CR: complete remission